Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 275

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 275
---
 |     |              | 64,879 |   |     |      | 64,879 |   |
| Warrants                                               |     |              |  4,524 |   |     |      |      - |   |
| Weighted-average shares outstanding, basic and diluted |     |              | 69,403 |   |     |      | 64,879 |   |
| Net loss per share, basic and diluted                  |     |              |  (60.2 | ) |     |      |  (22.0 | ) |

On August 15, 2023, the Company issued
11,965 warrants (please refer to Note 11). The warrants were considered exercisable for little to no consideration and are therefore
included in basic shares outstanding at their issuance date.

| n. | Accounting pronouncement recently adopted |

In February 2016, the FASB issued ASU
2016-02 “Leases” to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities
on the balance sheet and disclosing key information about leasing arrangements. For operating leases, the ASU requires a lessee to recognize
a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, on its balance sheet. The ASU
retains the current accounting for lessors and does not make significant changes to the recognition, measurement, and presentation of
expenses and cash flows by a Lessee.

Effective January 1, 2022, the Company
adopted the new lease accounting standard. The Company elected to apply the practical expedients permitted under the transition guidance
within the new standard. As such, there was no impact on the Company’s financial statements as a result of adopting ASU 2016-02.

<div align='center'>F-27</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 2:- | SIGNIFICANT ACCOUNTING POLICIES (Cont.) |

Effective January 1, 2023, the Company
adopted ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset
measured at amortized cost to be presented at the net amount expected to